Drugs /

cxcr4 inhibitor q-122

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of CXCR4 with potential antineoplastic and antiviral activities. CXCR4 inhibitor MSX-122 binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor-1 (SDF-1) to the CXCR4 receptor and receptor activation, which may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the GPCR (G protein-coupled receptor) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; it is also a co-receptor for HIV entry into T cells.

Clinical Trials

View Clinical Trials for cxcr4 inhibitor q-122

Cxcr4 inhibitor q-122 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating cxcr4 inhibitor q-122, 1 is phase 2 (0 open).

Breast carcinoma is the most common disease being investigated in cxcr4 inhibitor q-122 clinical trials [2].

Drug Details

Drug Target(s) [2]:
CXCR4
NCIT ID [1]:
C74022

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.